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Dear Editor,
We have read Kumar et al.’s study1 published in the previous is-
sue of Clinical and Molecular Hepatology  with great interest, 
which compared the characteristics and outcomes in patients with 
nonalcoholic steatohepatitis (NASH)-associated hepatocellular 
carcinoma (HCC) versus those with alcoholic steatohepatitis 
(ASH)-associated HCC. The study reported several differences in 
characteristics, such as age, sex, and comorbidities, between the 
two groups, whereas their survival rates as well as liver- and tu-
mor-related factors were comparable. Although the current study 
was a retrospective analysis of a single-center cohort, it still offers 
a number of relevant points for further consideration.
First, patients with nonalcoholic fatty liver disease (NAFLD) or 
alcohol-related liver disease (ALD) are prone to deficient surveil-
lance.2,3 Patients with undiagnosed alcohol-related cirrhosis also 
contribute to the low rate of surveillance as well as late diagnosis 
of HCC, due to their low compliance with regular appointments.4 
NASH-related cirrhosis is a well-known indication of surveillance 
for HCC. However, for patients with non-cirrhotic NASH (or even 
non-NASH NAFLD), there has been no consensus on whether to 
offer surveillance or not. In Kumar et al.’s study,1 the frequencies 
of non-cirrhotic patients with NASH-HCC and ASH-HCC were sim-
ilar, whereas significantly more patients with ASH-HCC were diag-
nosed with surveillance compared to those with NASH-HCC. The 
difference in surveillance possibly resulted from the small sample 
size, considering the low rate of surveillance and late diagnosis in 
both etiology groups.2,3 Older age in patients with NASH-HCC 
may result from the lower surveillance rate, as discussed in Kumar 
et al.’s study.1 Moreover, delayed diagnosis of HCC can lead to 
large tumor and poor outcomes in patients with NAFLD or ALD. 
Appropriate surveillance strategy for patients with NAFLD or ALD 
is urgently needed in order to discover more patients at earlier 
stages, when they are amenable to curative therapies. However, 
non-cirrhotic patients existed in both groups of Kumar et al.’s 
study,1 adding difficulty in selecting the target population for sur-
veillance.
Second, the presence of modifiable lifestyle factors and their 
impact on the outcome should be studied. In particular, there 
might have been NASH-HCC patients with nonsignificant 
(<60 g/day) alcohol consumption in Kumar et al.’s study,1 which 
otherwise could be defined as significant, if the amount exceeded 
>21 (14) standard drinks/week in men (women).5 The exact pro-
portion of NASH-HCC patients with alcohol consumption amount 
between 21 (14) standard drinks/week and <60 g/day is not as-
sessable, due to the lack of information. Likewise, obese ASH-
HCC patients (body mass index, ≥25 kg/m2) might also exist in 
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the study population. A recent study from a prospective European 
cohort demonstrated that smoking was an independent predictor 
of survival in hepatitis B or C-infected HCC patients.6 In addition, 
NASH-HCC patients suffer from various comorbidities, such as 
cardiovascular diseases.7 Therefore, multiple coexistence of life-
style risk factors or their comorbid conditions may differ at indi-
vidual level, and this needs to be verified from the preventive per-
spective.
Third, the interpretation of etiology-specific outcomes and their 
comparison requires caution, possibly due to selection bias. Previ-
ous studies reported controversial results, especially in terms of 
survival in NAFLD- or NASH-HCC patients. A prospective multi-
center observational study from Italy reported similar survival 
rates between NAFLD-HCC and hepatitis C virus (HCV)-related 
HCC groups after patient matching, where the difference in mor-
tality was driven by cardiovascular causes.8 Another Italian study 
showed negative effect of alcoholic etiology on survival compared 
to HCV-HCC, which disappeared after adjustment for confounding 
factors and stratification by tumor stage.2 In cohort studies to 
evaluate and compare etiology-specific outcomes, efforts are 
needed to adjust the differences in baseline characteristics (e.g., 
using a propensity score analysis) and to minimize lead-time bias, 
considering the imbalance in surveillance rates between groups.
In summary, Kumar et al.’s study1 provided intriguing yet diffi-
cult aspects of HCC management, with its epidemiology changing 
over the last decade. Viral etiologies that underscore the impor-
tance of lifestyle-related HCC, such as ALD or NAFLD-HCC, are 
anticipated to be controlled in the near future. Appropriate sur-
veillance strategy and early diagnosis based on larger-scale, well-
designed prospective studies may be the most challenging tasks 
for improving the outcome.
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